NCT00802893View on ClinicalTrials.gov

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Isolated Systolic HypertensionEndothelial Dysfunction
Interventions
DRUG

6R-BH4

6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period

OTHER

Placebo

placebo given BID for entire length of study

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

BioMarin Pharmaceutical
All Listed Sponsors
collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

Johns Hopkins University

OTHER